Uncomplicated UTIs cause distressing symptoms and loss of productivity in up to 10% of women annually (1). Some subgroups get recurrent symptoms (including 25% of women who have a UTI [2] ), and prophylactic use of cranberries has been a popular therapeutic suggestion with a biologically plausible basis. The earlier Cochrane review (3) provided some evidence for a weak effect of cranberries for prevention of UTIs in patients susceptible to recurrent UTIs. With the addition of 14 new studies, the updated review by Jepson and colleagues now shows the evidence to be even weaker than previously believed, with no difference in subsequent UTIs compared with placebo. The meta-analysis shows that antibiotics and cranberries do not differ for preventing recurrent UTIs. However, because this analysis was based on 3 small studies, 1 of which lost 32% of participants before follow-up, comparisons of the effectiveness of these interventions warrant caution. Similarly, analysis of 1 adult and 1 pediatric study suggests that patients taking cranberry products have fewer UTIs than do patients taking probiotics, for reasons that are unclear. The outcomes measured in trials often restrict the ability of reviewers to estimate the value of UTI treatments in terms of what matters to patients-symptoms. This is relevant as the goal of treatment is reduction of morbidity rather than microbiological cure. It is also pertinent given RCT evidence that about 33% of women who present with clinically identical UTI symptoms do not have detectable bacteriologic infection but do have a symptomatic response to empirical antibiotics (1). The high dropout rate in many studies suggests that patient acceptability of long-term use is not high, and this is likely to worsen outside of the research setting, where patients bear the cost. It seems that, unlike chocolate (4), cranberries should be recommended only for their culinary, rather than for therapeutic, potential. 
Commentary
Uncomplicated UTIs cause distressing symptoms and loss of productivity in up to 10% of women annually (1) . Some subgroups get recurrent symptoms (including 25% of women who have a UTI [2] ), and prophylactic use of cranberries has been a popular therapeutic suggestion with a biologically plausible basis. The earlier Cochrane review (3) provided some evidence for a weak effect of cranberries for prevention of UTIs in patients susceptible to recurrent UTIs. With the addition of 14 new studies, the updated review by Jepson and colleagues now shows the evidence to be even weaker than previously believed, with no difference in subsequent UTIs compared with placebo. The meta-analysis shows that antibiotics and cranberries do not differ for preventing recurrent UTIs. However, because this analysis was based on 3 small studies, 1 of which lost 32% of participants before follow-up, comparisons of the effectiveness of these interventions warrant caution. Similarly, analysis of 1 adult and 1 pediatric study suggests that patients taking cranberry products have fewer UTIs than do patients taking probiotics, for reasons that are unclear. The outcomes measured in trials often restrict the ability of reviewers to estimate the value of UTI treatments in terms of what matters to patients-symptoms. This is relevant as the goal of treatment is reduction of morbidity rather than microbiological cure. It is also pertinent given RCT evidence that about 33% of women who present with clinically identical UTI symptoms do not have detectable bacteriologic infection but do have a symptomatic response to empirical antibiotics (1). The high dropout rate in many studies suggests that patient acceptability of long-term use is not high, and this is likely to worsen outside of the research setting, where patients bear the cost. It seems that, unlike chocolate (4), cranberries should be recommended only for their culinary, rather than for therapeutic, potential. 
Review scope
Included studies compared cranberry juice or cranberry products (e.g., capsules, tablets, or extract) used for ≥ 1 month, with placebo, no treatment, or other treatment in susceptible men and women with > 2 lower UTIs in the past 12 months; elderly men and women; patients with indwelling catheters, abnormalities of the urinary tract, or needing intermittent catheterization; pregnant women; or children with ≥ 1 UTI. Studies of UTI treatment or urinary tract conditions not caused by bacterial infection were excluded. Outcomes were number of UTIs and adverse effects.
Review methods
This was an update of a previous review. Cochrane Renal Group's Specialised Register ( Jul 2012) (which includes studies identified from Cochrane Central Register of Controlled Trials, MED-LINE, EMBASE/Excerpta Medica, handsearches of renal-related journals and proceedings of major renal conferences, review of current awareness alerts for selected renal journals, and searches of International Clinical Trials Register Search Portal and ClinicalTrials.gov) was searched for randomized controlled trials (RCTs) and quasi-RCTs. 24 studies (n = 4473), including 10 from the previous review and 14 new studies (n = 3424), met the selection criteria. 11 studies (n = 2249) assessed a cranberry juice product, 9 (n = 1032) assessed cranberry tablets and capsules, 2 (n = 131) assessed liquid cranberry concentrate/syrup, 1 compared cranberry juice and tablets, and 1 compared cranberry capsules and tablets. Studies compared cranberry products with placebo, no treatment, water, Methenamine Hipurate, and antibiotics. 14 studies were at low risk for bias for random sequence generation, 15 were at low risk for bias for allocation concealment, and 17 reported adequate blinding of patients and study personnel.
Main results
Cranberry products did not reduce the number of patients with UTIs compared with placebo/control overall (Table) , nor in several subgroups. Cranberry products reduced symptomatic UTIs more than probiotics but not more than antibiotics; ≥ 2 doses/d did not reduce symptomatic UTIs more than 1 dose/d (Table) . Cranberry products did not increase risk for adverse events.
